Life-Threatening Bleeding After Dental Extraction in a Hemophilia A Patient With Inhibitors to Factor VIII: A Case Report

Journal of Oral and Maxillofacial Surgery

Volumn 61, Issue 11, 2003, Pages 1350-1353

  Heiland, Max ^a   Weber, Martin ^b   Schmelzle, Rainer ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; FATALITY; HEMOGLOBIN DETERMINATION; HEMOPHILIA A; HUMAN; MALE; POSTOPERATIVE HEMORRHAGE; SIDE EFFECT; SUTURING METHOD; TOOTH EXTRACTION;

EID: 0242381152     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-2391(03)00739-0     Document Type: Article

References (23)

1. Brackmann HH, Lenk H, Scharrer I, et al: German recommen dations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 5:203, 1999
2. Aledort LM: Inhibitors in haemophilia patients. Current status and management. Am J Hematol 47:208, 1994
3. Ehrenforth S, Kreuz W, Scharrer I, et al: Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594, 1992
4. Hay CR: Why do inhibitors arise in patients with haemophilia A? Br J Haematol 105:584, 1999
5. Schwaab R, Brackmann HH, Meyer C, et al: Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 74:1402, 1995
6. Hay CR: Acquired haemophilia. Baillieres Clin Haematol 11: 287, 1998
7. Knöbl P, Derfler K: Extracorporal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 77:57, 1999 (suppl 1)
8. Brackmann HH, Oldenburg J, Schwaab R: Immune tolerance for the treatment of factor VIII inhibitors - twenty years "Bonn protokoll." Vox Sang 70:30, 1996 (suppl 1)
9. Oldenburg J, Schwaab R, Brackmann HH: Induction of immune tolerance in haemophila A inhibitor patients by the Bonn protocol. Predictive parameter for therapy duration and outcome. Vox Sang 77:49, 1999 (suppl 1)
10. Nilsson IM, Berntorp E, Zettervall O: Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 318:947, 1988
11. Green D, Rademaker W, Briet E: A prospective, randomised trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 60: 753, 1993
12. Brox AG, Laryea H, Pelletier M: Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol 57:87, 1998
13. Turecek PL, Varadi K, Auer W, et al: Factor Xa and prothrombin: Mechanism of action of FEIBA. Vox Sang 77:72, 1999 (suppl 1)
14. Hilgartner MW, Knatterud GL, the FEIBA Study Group: The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 61:36, 1983
15. Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, et al: The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 305:717, 1981
16. Scharrer I: Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency. Haemophilia 5:253, 1999
17. Schulte W: Über den primären Nahtverschluβ nach intraoralen Eingriffen am Kieferknochen und die Defektversorgung mit Gelatineschwamm, Penicillin und Thrombin. Dtsch Zahnärztl Z 14:456, 1959
18. Wepner F: Die Wundversiegelung mit dem Fibrinklebesystem Tissucol™ bei Patienten mit hämorrhagischen Diathesen. Stomatol DDR 34:390, 1984
19. Werner, HO, Bschorer R, Keese E, et al: Lebensbedrohliche Nachblutungen im zahnärztlichen Notdienst. Dtsch Zahnärztl Z 52:61, 1997
20. Schmelzle R: Zahnärztlich-chirurgische Eingriffe beim thrombozytopenischen Risikopatienten. Dtsch Zahnärztl Z 41:400, 1986
21. Handin RI: Disorders of coagulation and thrombosis, in Braunwald E, Fauci AS, Kasper DL, et al (eds): Harrison's Principles of Internal Medicine (ed 15). New York, NY, McGraw-Hill 2001, p 752
22. DellaCroce FJ, Kountakis S, Aguilar EF III: Manifestations of factor VIII inhibitor in the head and neck. Arch Otolaryngol Head Neck Surg 125:1258, 1999
23. Shastri KA, Logue GL, Zeid MY, et al: Acquired factor VIII inhibitor with squamous cell cancer of the epiglottis. Arch Otolaryngol Head Neck Surg 116:350, 1990